# Chemical and Biological Defense Program - EMD — Program Element 0604384BP

**Program element:** 0604384BP  
**Component:** Defense-Wide  
**Appropriation:** 0400 — RDT&E, Defense-Wide  
**Budget Activity:** 5 — System Development & Demonstration  
**Vintage:** President's Budget PB2027  
**Canonical URL:** https://hitchintel.com/programs/0604384BP

## Summary

Defense-Wide requests $261.9M in FY2027 — the program's peak. In the FY2027 defense authorization, the House cut 10% (to $234.4M); the Senate funded it in full; House appropriators funded it in full. FLIR Systems leads the industry work.

## Funding profile

| Fiscal Year | Estimate Type | Amount ($M) |
|---|---|---|
| FY2025 | Actual | 251.4 |
| FY2026 | Enacted | 231.5 |
| FY2027 | Request | 261.9 |
| FY2028 | Outyear | 255.6 |
| FY2029 | Outyear | 207.8 |
| FY2030 | Outyear | 188.6 |
| FY2031 | Outyear | 190.8 |

> Estimate types are not summed — the profile mixes actuals, enacted law, the request, and outyear projections.

## Congressional marks (FY2027)

| Stage | Marked ($M) | Change ($M) |
|---|---|---|
| Request | 261.9 | — |
| House NDAA (HASC) | 234.4 | −27.5 |
| Senate NDAA (SASC) | 261.9 | +0.0 |
| House Approps (HAC-D) | 261.9 | +0.0 |

> FY2027 NDAA authorization marks, as of 2026-07-27. Not appropriations or final law.

## Projects (4)

| Project | Title | FY2025 actual | FY2026 enacted | FY2027 request | Move |
|---|---|---|---|---|---|
| UN5 | Understand (SDD) | 145.0 | 144.2 | 187.9 | +30% |
| MT5 | Mitigate (SDD) | 58.3 | 44.9 | 44.0 | −2% |
| PT5 | Protect (SDD) | 40.3 | 36.7 | 25.6 | −30% |
| EN5 | Enabling Investments (SDD) | 7.8 | 5.8 | 4.5 | −23% |

> Projects are the summable leaves: the program element total is their sum, never added to it.

### Project UN5 — Understand (SDD)

The Understand System Development & Demonstration (SDD) Project provides the Joint Force the ability to continually receive information about the chemical and biological (CB) situation at a desired time and place by detecting, identifying, and quantifying CB hazards in air, water, or on land, and on personnel, equipment or facilities. These efforts support the ability to conduct early warning (informing protective posture) and employment of rapid detection, identification, and analysis tools needed to address emerging biological threats. Efforts also keep the Joint Force ahead of emerging chemical threats with portable, reduced size, weight, and power, cost detectors to protect general and specialized forces and to enhance operations on the battlefield by providing early warning and field analytics. Medical diagnostic activities develop U.S. Food & Drug Administration (FDA) approved products for the warfighter at the point of care to inform far-forward medical and protection decisions. Efforts included in this Project are: (1) Advanced Differential Diagnostics (ADD) (2) Advanced and Emerging Threat Defense (AET DEFENSE) (3) Aerosol Vapor Chemical Agent Detector (AVCAD) (4) Chemical and Biological Wearables (CB WEARABLES) (5) Chemical and Biological Wearables - Enhanced Biological Defense (CB WEARABLES- ENBD) (6) Colorimetric Indicator (CIND) (7) Chemical Biological Radiological Nuclear Sensor Integration on Robotics Platforms (CSIRP) (8) Compact Vapor Chemical Agent Detector (CVCAD) (9) Defense Biological Products Assurance Program (DBPAP) (10) Defense Biological Products Assurance Program - Enhanced Biological Defense (DBPAP-ENBD) (11) Distributed Threat Agnostic Networked Sensing (DISTANS) (12) Far Forward Biological Sequencing (FFBS) - Increment 1 (13) Far Forward Biological Sequencing (FFBS) - Increment 2 (14) Mobile Field Kit (MFK) (15) Nuclear Biological Chemical Reconnaissance Vehicle Sensor Suite Upgrade (NBCRV SSU) (16) Chemical Biological Radiological Nuclear Reconnaissance Modular Mission Payload (CRMMP) (17) Next Generation Diagnostics System 2 Chemical Diagnostics (NGDS 2 CHEMDX) (18) Next Generation Diagnostics System 2 Man Portable Diagnostic System (NGDS 2 MPDS) (19) Non-targeted Sequencing Identification System (NSIS) (20) Proximate Chemical Agent Detector (PCAD) (21) Special Purpose Unit Rapid Capability Development and Deployment (SPU…

**Named R-3 performers** (share of this project's FY2027 R-3 total, so they need not reach 100%)**:** FLIR Systems (22.7, 12%), Advanced (5.0, 2.7%), Philips North America (4.3, 2.3%), Capability Program Executive Chemical, B (3.1, 1.7%).

| Activity (R-2A) | FY2025 | FY2026 | FY2027 |
|---|---|---|---|
| 1) Advanced Differential Diagnostics (ADD) | — | 1.9 | 11.2 |
| 2) Advanced and Emerging Threat Defense (AET DEFENSE) | 1.8 | 2.2 | 1.9 |
| 3) Aerosol Vapor Chemical Agent Detector (AVCAD) | 5.6 | 6.0 | 3.4 |
| 4) Chemical and Biological Wearables (CB WEARABLES) | — | 9.0 | 10.0 |
| 5) Chemical and Biological Wearables - Enhanced Biological Defense (CB WEARABLES-ENBD) | 24.7 | 23.9 | 19.8 |
| 6) Colorimetric Indicator (CIND) | — | — | 2.8 |
| 7) Chemical Biological Radiological Nuclear Sensor Integration on Robotic Platforms (CSIRP) | 16.6 | 21.2 | — |
| 8) Compact Vapor Chemical Agent Detector (CVCAD) | 8.1 | 16.2 | 13.3 |
| 9) Defense Biological Products Assurance Program (DBPAP) | 7.8 | 7.6 | 9.0 |
| 10) Defense Biological Products Assurance Program - Enhanced Biological Defense (DBPAP-ENBD) | 2.0 | 2.0 | 2.1 |
| 11) Distributed Threat Agnostic Networked Sensing (DISTANS) - CBRN Remote Sensing | — | — | 11.3 |
| 12) Far Forward Biological Sequencing (FFBS) - Increment 1 | 5.4 | 1.4 | — |
| 13) Far Forward Biological Sequencing (FFBS) - Increment 2 | — | — | 4.6 |
| 14) Mobile Field Kit (MFK) | 6.5 | 1.9 | — |
| 15) Nuclear Biological Chemical Reconnaissance Vehicle Sensor Suite Upgrade (NBCRV SSU) | 20.8 | 25.4 | — |
| 16) Chemical Biological Radiological Nuclear Reconnaissance Modular Mission Payload (CRMMP) | — | — | 39.9 |
| 17) Next Generation Diagnostics System 2 Chemical Diagnostics (NGDS 2 CHEMDX) | 2.1 | 1.4 | — |
| 18) Next Generation Diagnostics System 2 Man Portable Diagnostic System (NGDS 2 MPDS) | 14.3 | 7.9 | 4.3 |
| 19) Non-targeted Sequencing Identification System (NSIS) | — | 1.4 | 4.3 |
| 20) Proximate Chemical Agent Detector (PCAD) | 6.2 | 4.2 | 3.1 |
| 21) Special Purpose Unit Rapid Capability Development and Deployment (SPU RCDD) | 7.0 | 7.2 | 15.2 |
| 22) Wearable All-hazard Remote-monitoring Program (WARP) - WARP Prototype Development | 2.6 | 3.2 | — |
| 23) Wearable All-hazard Remote-monitoring Program (WARP) - Test & Evaluation | 1.5 | — | — |
| 24) Wearable All-hazard Remote-monitoring Program (WARP) - Monitor for Acute CBRN Exposure | — | — | 31.7 |
| 25) Joint Biological Tactical Detection System (JBTDS) | 12.1 | — | — |

> R-2A activities carry the prior, current and budget year only — no five-year plan. Coverage is partial, so count them, never total them.

### Project MT5 — Mitigate (SDD)

The Mitigate System Development & Demonstration (SDD) Project provides the Joint Force the ability to recover from exposure to chemical and biological hazards and quickly return to the fight. Efforts include development of U.S. Food & Drug Administration (FDA) approved medical countermeasures (MCMs) to protect the lives and maintain the battle readiness of the warfighter. Efforts also provide safe, effective MCMs to enable warfighter recovery and return to duty after exposure to chemical threat agents, and reduce logistics needs of decontamination methods with operationally-relevant test methods and allows personnel to reduce Mission-Oriented Protective Posture (MOPP) levels as rapidly as possible. Activities in this project realize considerable efficiencies through cost sharing agreements. Efforts included in this Project are: (1) Alternative Autoinjector Manufacturer Capability (AUTOINJ) - RAD-A (2) Anti-Viral Oral Therapeutics (AVO TX) - Non-Clinical Studies (3) Countering Emerging Threats Rapid Acquisition and Investigation of Drugs for Repurposing (CET RAIDR) (4) CET RAIDR - Enhanced Biological Defense (CET RAIDR-ENBD) (5) Forward Area Mobility Spray System (FAMS-S) - Aircraft Interior Decon (AID) (6) Service Equipment Decontamination System (SEDS) (7) Tactical Contamination Mitigation System (TCMS) (8) Improved Nerve Agent Treatment System Centrally Acting (INATS CA) - Non-Clinical

| Activity (R-2A) | FY2025 | FY2026 | FY2027 |
|---|---|---|---|
| 1) Alternative Autoinjector Manufacturer Capability (AUTOINJ) - RAD-A | 15.6 | 5.8 | — |
| 2) Anti-Viral Oral Therapeutics (AVO TX) - Non-Clinical Studies | — | 3.8 | 12.5 |
| 3) Countering Emerging Threats Rapid Acquisition and Investigation of Drugs for Repurposing (CET RAIDR) | 15.4 | 15.7 | 16.5 |
| 4) Countering Emerging Threats Rapid Acquisition and Investigation of Drugs for Repurposing - Enhanced Biological Defense (CET RAIDR-ENBD) | 7.3 | 7.3 | 7.5 |
| 5) Forward Area Mobility Spray System (FAMS-S) - Aircraft Interior Decon (AID) | — | — | 2.5 |
| 6) Service Equipment Decontamination System (SEDS) | 11.9 | 5.7 | — |
| 7) Tactical Contamination Mitigation System (TCMS) | — | 6.5 | 5.1 |
| 8) Improved Nerve Agent Treatment System Centrally Acting (INATS CA) - Non-Clinical | 8.1 | — | — |

> R-2A activities carry the prior, current and budget year only — no five-year plan. Coverage is partial, so count them, never total them.

### Project PT5 — Protect (SDD)

The Protect System Development & Demonstration (SDD) Project enhances mission performance and provides effective protection against current and emerging threats by rapidly developing and fielding modernized protection capabilities. Developmental efforts focus on advances in materials and systems engineering to enhance protective properties against a broader array of hazards, while reducing operational challenges and logistical burdens. Developmental efforts focus on advanced medical countermeasures that provide safe and effective medical defenses against biological agents (bacteria, toxins, and viruses), emerging infectious diseases, and chemical agents. Efforts included in this Project are: (1) Advanced System for Protection and Integration Reduction of Encumbrances (ASPIRE) (2) Advanced System for Protection and Integration Reduction of Encumbrances - Enhanced Biological Defense (ASPIRE-ENBD) (3) Biological Containment Isolation System - Enhanced Biological Defense (BCIS-ENBD) (4) Portable Patient Transport System - Enhanced Biological Defense (PPTS-ENBD) (5) Rapid Access to Products in Development (RAPID) (6) Shipboard Isolation System (SIS) (7) Uniform Integrated Protective Ensemble Family of Systems Gloves (UIPE FOS GLOVES) (8) Uniform Integrated Protective Ensemble Family of Systems General Purpose (UIPE FOS GP) (9) Next Generation Individual Protection (NG IP) (10) Botulinum Monoclonal Antibodies (BOT MAB) – Manufacturing/Clinical/Non Clinical (11) Vaccine Acceleration By Modular Progression - Enhanced Biological Defense (VAMP-ENBD)

**Named R-3 performers** (share of this project's FY2027 R-3 total, so they need not reach 100%)**:** Fisher BioServices (0.9, 3.5%), Henry M. Jackson Foundation for the Adva (0.5, 1.9%), DynPort Vaccine (0.3, 1.2%).

| Activity (R-2A) | FY2025 | FY2026 | FY2027 |
|---|---|---|---|
| 1) Advanced System for Protection and Integration Reduction of Encumbrances (ASPIRE) | 6.5 | — | — |
| 2) Advanced System for Protection and Integration Reduction of Encumbrances - Enhanced Biological Defense (ASPIRE-ENBD) | 1.9 | 1.1 | — |
| 3) Biological Containment Isolation System - Enhanced Biological Defense (BCIS-ENBD) | — | 1.6 | 3.5 |
| 4) Portable Patient Transport System - Enhanced Biological Defense (PPTS-ENBD) | — | 4.1 | 3.2 |
| 5) Rapid Access to Products in Development (RAPID) | 9.9 | 8.3 | 8.5 |
| 6) Shipboard Isolation System (SIS) | — | 4.2 | 3.8 |
| 7) Uniform Integrated Protective Ensemble Family of Systems Gloves (UIPE FOS GLOVES) | 6.5 | 7.4 | 0.9 |
| 8) Uniform Integrated Protective Ensemble Family of Systems General Purpose (UIPE FOS GP) | 5.9 | 9.9 | — |
| 9) Next Generation Individual Protection (NG IP) | — | — | 5.8 |
| 10) Botulinum Monoclonal Antibodies (BOT MAB) - Manufacturing/Clinical/Non Clinical | 4.7 | — | — |
| 11) Vaccine Acceleration By Modular Progression - Enhanced Biological Defense (VAMP-ENBD) | 5.0 | — | — |

> R-2A activities carry the prior, current and budget year only — no five-year plan. Coverage is partial, so count them, never total them.

### Project EN5 — Enabling Investments (SDD)

The Enabling Investments System Development & Demonstration (SDD) Project provides the capability to rapidly develop, manufacture, and approve medical countermeasures through sustaining the Department of War advanced development manufacturing facility. Enabling efforts in this area support dedicated infrastructure capabilities, demonstrations, and overarching development support functions as portfolio enablers responding to emerging threats. Additional efforts facilitate incorporation of chemical and biological (CB) survivability equipment into service major acquisition programs. Efforts included in this Project are: (1) Chemical Biological Incident Preparedness and Response - Secure Biolaboratory Consortium (CBIPR-SBC) (2) Major Defense Acquisition Program (MDAP)

| Activity (R-2A) | FY2025 | FY2026 | FY2027 |
|---|---|---|---|
| 1) Chemical Biological Incident Preparedness and Response - Secure Biolaboratory Consortium (CBIPR-SBC) | 4.9 | 5.8 | 4.5 |
| 2) Major Defense Acquisition Program (MDAP) | 2.9 | — | — |

> R-2A activities carry the prior, current and budget year only — no five-year plan. Coverage is partial, so count them, never total them.

## Where the FY2027 request goes

| Category | Share | $M |
|---|---|---|
| Industry primes | 22% | 58.8 |
| Government labs & warfare centers | 6.2% | 16.3 |
| Other / unspecified | 71% | 186.9 |

**Top named industry performers:** FLIR Systems ($22.7M, 8.6%).

> R-3 exhibit contract funding, not USAspending obligations.

## Mission & acquisition strategy

This program element (PE) resources System Development & Demonstration across the Understand, Protect, Mitigate, and Enabling Investments portfolios. Chemical and Biological Defense Program (CBDP) investments provide an integrated, layered capability to enable Department of War (DoW) missions in a chemical and biological environment, ranging from combat operations to domestic incident prevention and response. The projects in this PE support the development, build, and test of products to verify that all operational and derived requirements have been met and to support production or deployment decisions.

Advanced Differential Diagnostics (ADD) The Advanced Differential Diagnostics (ADD) program will utilize Other Transaction Authority (OTA) project agreements to identify, competitively prototype, and mature commercial solutions deemed technologically viable, and evaluate them in as realistic an operational environment as possible. Successful candidate systems will transition to the Engineering and Manufacturing Development phase to be further developed under the OTA agreement, in order to satisfy military and U.S. Food & Drug Administration (FDA) regulatory requirements for subsequent production and fielding to the services. Upon FDA clearance of the first ADD capability the ADD program will seek a Milestone (MS) C decision.

## Related program elements

- [0603884BP — Chemical and Biological Defense Program - Dem/Val](https://hitchintel.com/programs/0603884BP) (Defense-Wide)
- [0607384BP — Chemical and Biological Defense (Operational Systems Development)](https://hitchintel.com/programs/0607384BP) (Defense-Wide)
- [0604134A — Counter Improvised-Threat Demonstration, Prototype Development, and Testing](https://hitchintel.com/programs/0604134A) (Army)
- [0604746A — Automatic Test Equipment Development](https://hitchintel.com/programs/0604746A) (Army)

## Source & machine access

- **Source:** FY2027 Office of the Secretary of Defense RDT&E Budget Justification, Exhibits R-2/R-3, PE 0604384BP (PB PB2027); FY2027 NDAA committee marks (as of 2026-07-27).
- **MCP:** `mcp.hitchintel.com` — `budget_get_program_element(pe="0604384BP")`.

*HitchAI is an independent intelligence service, not affiliated with the U.S. Department of Defense. Budget figures are requests/estimates, not obligations.*